Published in Science on May 21, 2004
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet (2007) 10.92
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
The personal genome project. Mol Syst Biol (2005) 5.47
COSMIC 2005. Br J Cancer (2006) 5.07
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell (2011) 2.46
A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol (2005) 2.41
Inside the human cancer tyrosine phosphatome. Nat Rev Cancer (2011) 2.38
Two reciprocal translocations provide new clues to the high mutability of the Grid2 locus. Mamm Genome (2005) 2.35
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood (2006) 2.28
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol (2010) 2.02
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A (2007) 1.87
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. FEBS J (2013) 1.68
Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med Genomics (2014) 1.53
Cancer genome sequencing--an interim analysis. Cancer Res (2009) 1.52
Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol (2007) 1.40
Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene (2012) 1.36
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther (2005) 1.34
Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev (2008) 1.32
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30
Molecular analysis of receptor protein tyrosine phosphatase mu-mediated cell adhesion. EMBO J (2006) 1.28
Systems pharmacology and genome medicine: a future perspective. Genome Med (2009) 1.26
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
PTPN14 is required for the density-dependent control of YAP1. Genes Dev (2012) 1.23
Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis (2009) 1.23
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. Cancer Res (2010) 1.18
PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene (2012) 1.17
DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One (2011) 1.16
Mutations of KCNJ10 together with mutations of SLC26A4 cause digenic nonsyndromic hearing loss associated with enlarged vestibular aqueduct syndrome. Am J Hum Genet (2009) 1.16
Genome-wide association study identifies novel loci associated with resistance to bovine tuberculosis. Heredity (Edinb) (2014) 1.15
Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J Virol (2006) 1.14
Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes. Oncotarget (2015) 1.13
Our changing view of the genomic landscape of cancer. J Pathol (2010) 1.13
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A (2008) 1.13
Human POLB gene is mutated in high percentage of colorectal tumors. J Biol Chem (2012) 1.12
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion. Mol Cancer Res (2008) 1.11
The protein tyrosine phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and organ development. J Cell Biol (2007) 1.11
Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin (2014) 1.10
Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics (2006) 1.10
A gene-alteration profile of human lung cancer cell lines. Hum Mutat (2009) 1.09
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev (2011) 1.06
Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development. Mol Cell Biol (2006) 1.06
Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation . Biochemistry (2009) 1.04
Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem (2014) 1.04
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res (2007) 1.01
Copy number variants in patients with short stature. Eur J Hum Genet (2013) 1.01
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene (2009) 1.01
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01
PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev (2008) 1.00
Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. Cell Adh Migr (2012) 1.00
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J (2005) 0.99
Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am J Hum Genet (2010) 0.99
Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants. World J Biol Chem (2014) 0.99
Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res (2011) 0.98
Mutated genes, pathways and processes in tumours. EMBO Rep (2010) 0.97
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer (2009) 0.97
A novel computational biostatistics approach implies impaired dephosphorylation of growth factor receptors as associated with severity of autism. Transl Psychiatry (2014) 0.96
Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J (2009) 0.95
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol (2007) 0.95
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res (2010) 0.95
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer (2008) 0.95
From cancer genomes to cancer models: bridging the gaps. EMBO Rep (2009) 0.95
The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS One (2013) 0.95
High sensitivity EndoV mutation scanning through real-time ligase proofreading. Nucleic Acids Res (2004) 0.94
Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J (2013) 0.93
Protein tyrosine phosphatases in glioma biology. Acta Neuropathol (2009) 0.92
Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol (2006) 0.92
Intrinsic fluctuations, robustness, and tunability in signaling cycles. Biophys J (2007) 0.92
PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med Chem (2011) 0.92
Allele-specific inhibition of divergent protein tyrosine phosphatases with a single small molecule. Bioorg Med Chem (2008) 0.92
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer (2009) 0.91
Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep (2011) 0.91
PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J Biol Chem (2014) 0.90
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J Cancer Res Clin Oncol (2009) 0.90
Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol (2009) 0.90
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14. Oncogene (2012) 0.89
Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J (2009) 0.89
PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization. Oncogene (2010) 0.89
Genome wide identification of recessive cancer genes by combinatorial mutation analysis. PLoS One (2008) 0.88
Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells. Cancer Biol Ther (2012) 0.88
Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochim Biophys Acta (2014) 0.88
Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease. J Cell Commun Signal (2012) 0.88
Identification and expression of the family of classical protein-tyrosine phosphatases in zebrafish. PLoS One (2010) 0.87
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. PLoS One (2012) 0.87
Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations. Expert Rev Proteomics (2009) 0.86
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer. J Cancer Res Clin Oncol (2013) 0.86
A genome-wide screen for genetic variants that modify the recruitment of REST to its target genes. PLoS Genet (2012) 0.86
Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene (2014) 0.86
Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation. Cell Commun Adhes (2009) 0.86
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
International network of cancer genome projects. Nature (2010) 20.35
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36